Skip to content
Everest Medicines
-
Everest Medicines announces ambitious 2030 growth strategy as leadership raises stakes
Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.
-
Everest Medicines expands its cardiovascular portfolio through strategic collaboration with Hasten Biopharmaceuticals
The collaboration is designed to strengthen Everest’s commercial operations in China while expanding its presence in the cardiovascular disease market.